Compare IPHA & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | EVC |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 335.0M |
| IPO Year | 2014 | 2000 |
| Metric | IPHA | EVC |
|---|---|---|
| Price | $1.87 | $8.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | 52.7K | ★ 1.2M |
| Earning Date | 03-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.35% |
| EPS Growth | N/A | ★ 47.59 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $536,034,000.00 |
| Revenue This Year | $180.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $1.95 |
| 52 Week High | $2.71 | $13.74 |
| Indicator | IPHA | EVC |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 43.70 |
| Support Level | $1.67 | $7.72 |
| Resistance Level | $1.95 | $10.09 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 0.00 | 88.37 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.